IgGenix Demonstrates Potential for Single-Cell RNA-Sequencing in Tree Nut Allergies
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly alleviate allergic disease, today announced insights from its novel SeqSifter™ single-cell RNA-sequencing discovery platform demonstrating the potential for IgE antibody re-engineering in tree nut allergy. These data will be presented during the 2022 European Academy...
